Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer

Robert Dreicer, MD
Published: Thursday, Mar 23, 2017



Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

The decision whether to treat a patient with either abiraterone or enzalutamide as initial treatment usually depends on the patient profile. Abiraterone requires low-dose prednisone, while enzalutamide has potential CNS toxicities, which allows clinicians to choose the most appropriate treatment based on each individual patient.
 
SELECTED
LANGUAGE


Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

The decision whether to treat a patient with either abiraterone or enzalutamide as initial treatment usually depends on the patient profile. Abiraterone requires low-dose prednisone, while enzalutamide has potential CNS toxicities, which allows clinicians to choose the most appropriate treatment based on each individual patient.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x